DC Bead LUMI, the first commercially available radiopaque drug-eluting bead for liver cancers, has received CE Mark.- BTG plc

BTG plc, a global specialist healthcare company, announced it has received Class III CE Mark certification for DC Bead LUMI, the first commercially available radiopaque drug-eluting bead (DEB) in the EU which can be loaded with doxorubicin or irinotecan for the local treatment of tumours in patients with hepatocellular carcinoma (HCC) and malignant colorectal cancer metastasised to the liver (mCRC). For the first time, DC Bead LUMI provides real-time visible and lasting confirmation of bead location, bringing a new level of control to transarterial chemoembolisation (TACE) procedures. DC Bead LUMI is a next-generation development of DC Bead, the market leading drug-loadable embolic bead.

Comment: The beads can be loaded with either doxorubicin or irinotecan, commonly used chemo agents, and injected into tumors within the liver. Their radiopaque quality, thanks to a compound called tri-iodobenzyl, allows these devices to be tracked using standard CT scans, confirming their correct placement.